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Abstract
Background: Sedatives are administered to 85 % of intensive care unit (ICU) patients. The most commonly used
sedatives are intravenous benzodiazepines and propofol. These agents are associated with over-sedation in 40 to
60 % of patients, which can lead to prolonged intubation, delirium and drug-induced hypotension. Evidence is
increasing that volatile anesthetic agents are associated with faster extubation times, improved cardiovascular
stability with no end-organ toxicity in comparison to our standard intravenous agents for short-term critical care
sedation. Use of volatile agents within the ICU is a novel technique using a specialized delivery and scavenging
system, which requires staff training and cultural acceptance. This pilot randomized controlled trial aims to assess
the safety and feasibility of delivering volatile agents for long-term patient sedation in the ICU with limited or no
experience of this technique.
Methods/Design: This is a prospective multicenter pragmatic pilot RCT that is blinded to the data analyst. This
study aims to recruit 60 adult ICU patients requiring mechanical ventilation and sedation for more than 48 h. Patients
will be randomized 2:1 to receive inhaled isoflurane (40 patients) or intravenous midazolam and/or propofol
(20 patients) sedation. Sedation is titrated to a targeted Sedation Analgesia Score (SAS) using an explicit
sedation-analgesia algorithm until extubation or tracheostomy. Primary safety and feasibility outcomes will
assess atmospheric volatile concentration levels and adherence to our sedation-analgesia protocol. Secondary
outcomes include time to extubation, duration of ventilation, quality of sedation, delirium, vasoactive drug
support, length of stay, serum fluoride levels and mortality.
Discussion: This pilot project will serve as the basis for a larger RCT that will be powered for important
clinical outcomes.
Trial Registration: ClinicalTrials.gov, NCT01983800 (registration date 2 July 2013).
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Background
Sedation is a cornerstone of patient care within intensive
care units (ICU). Sedative and analgesic medications are
administered to 85 % of ICU patients to assist tolerance
of mechanical ventilation and invasive procedures and to
treat anxiety and pain [1]. Current national and inter-
national sedation practice predominantly uses systemic
opioids to provide analgesia combined with intravenous
benzodiazepines (BDZ) in 60 % and propofol in 20 % of
patients [2, 3]. Suboptimal sedation is a commonly seen
phenomenon in 75 % patients [4]. Under-sedation oc-
curs in 30 % of patients, resulting in agitated patients
demonstrating hypercatabolism and hemodynamic in-
stability with a risk of self-harm and accidental extuba-
tion. More commonly, over-sedation from high doses is
seen in 40 to 60 % of patients [4]. Over-sedation is
linked to slow emergence with a delay in the return of
airway reflexes, which prolongs the duration of intub-
ation and mechanical ventilation, thereby increasing the
risk of acquiring ventilator-associated pneumonia [4, 5].
Elimination of BDZ, propofol, and opioids rely on good
synthetic liver and renal function [5]. Deep sedation is
compounded by slow clearance of these agents and sys-
temic drug accumulation among ICU patients who are
advancing in age and commonly have liver and renal
dysfunction. The daily cost of a ventilated patient ranges
$ 3500 to 6000, and thus, the economic impact of add-
itional ventilation days attributable to over-sedation is
significant [6].
Sedatives that are currently used are also associated
with delirium, which affects up to 80 % of ICU patients
[7]. This syndrome is characterized by an acute onset,
change or fluctuation in mental status plus inattention,
and disorganized thinking or an altered level of
consciousness. It is diagnosed at the bedside using
the highly reliable tools of the Confusion Assessment
Method (CAM-ICU) or Intensive Care Delirium
Screening Checklist (ICDSC) [7]. Delirium is associ-
ated with a prolonged hospital stay, increased ICU
and hospital costs (39 and 31 %, respectively) and
contributes to long-term cognitive dysfunction [7–11].
The etiology is multifactorial, but deep sedation
(coma) with heavy and prolonged use of BDZ is a
well-established risk factor (odds ratio 3.0, 95 % con-
fidence interval 1.3 to 6.8) for its development [8].
Additional concerns surrounding currently used agents
include the association of BDZ with the increased long-
term risk of developing psychiatric disorders such as anx-
iety, depression, and post-traumatic stress disorder, which
affects more than one-quarter of ICU survivors [12, 13].
The duration of sedation and the use of BDZ are con-
firmed risk factors for developing all three disorders
(mean difference 6.73, 95 % confidence interval 1.42 to
12.06) [12]. Prolonged use of propofol is associated with
hypertriglyceridemia, pancreatitis, myoclonus and the
rare condition of propofol infusion syndrome, which
causes cardiac and renal failure [5, 14]. Over-sedation
from these agents, particularly with propofol, also
promotes drug-induced hypotension necessitating the
use of vasoactive drug support. [5] In 2013, the Soci-
ety of Critical Care Medicine revised and updated
guidelines for the combined management of pain, agi-
tation, delirium (PAD) and recommended the routine
assessment of these three interrelated variables, use of
lighter sedation regimes, and non-BDZ sedative drugs [5].
The use of volatile anesthetic agents is routinely
applied within the operating room to provide general
anesthesia. Their use as an ICU sedative appears attract-
ive given these agents are simple to titrate, produce no
active metabolites, and are predominantly cleared un-
changed by pulmonary exhalation [15]. There are several
trials demonstrating these agents promote faster extuba-
tion times and better hemodynamic stability with no
renal or hepatic toxicity when used for short-term post-
operative sedation in comparison to propofol or BDZ
sedation [16–18]. Within a RCT of 139 cardiac surgical
patients, our group demonstrated that those who re-
ceived volatile-based anesthesia and postoperative sed-
ation extubated significantly faster by approximately
100 min in comparison to patients who received
intravenous propofol [19]. In 2011, Mesnil et al. dem-
onstrated that these agents not only provide faster
extubation times but also provide analgesia with a re-
duction in morphine use and a superior quality of
sedation with fewer dose titrations per day when used
for up to 96 h [20].
Delivery of volatile agents in the ICU can be sim-
ply performed using a small lightweight and portable
vaporizer called the Anesthesia Conserving Device
(AnaConDa™, Sedana Medical, Sweden). Volatile
agents (isoflurane or sevoflurane) are infused into
the device, which vaporizes the agent for inhalation.
This device is highly efficient and capable of recyc-
ling more than 90 % of the expired volatile agent, which
facilitates low infusion rates (commonly <5 ml/h) of
these agents. This set-up requires scavenging of the
volatile gases from the breathing circuit to minimize
atmospheric pollution and to ensure workplace
safety. Scavenging can be performed within the ICU
using charcoal passive absorption or active tech-
niques. [16, 21, 22] Volatile compounds contain
fluoride, whose high levels have been historically as-
sociated with high-output renal failure caused by an
older agent called methoxyflurane, which is no longer
used in clinical practice [23]. Studies using the mod-
ern volatiles isoflurane or sevoflurane have not
shown an association with raised fluoride levels and
renal toxicity for limited duration of use [16, 22, 24].
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Volatile agents are attractive and theoretically ideal
ICU sedatives. However, there is limited experience
with the use of these agents for several days. Further-
more, use of these agents and the AnaConDa™ system
in critical care units requires staff training and cultural
acceptance of this novel modality. Prior to undertaking
a large RCT to determine whether these agents provide
superior clinical outcomes to our current standard of
care, several safety and feasibility issues must be ad-
dressed. These issues form the focus of this pilot trial.
Methods/design
Study setting
This is a two-arm prospective multicenter pragmatic
pilot RCT comparing the safety and feasibility outcomes
of conducting long-term ICU sedation using inhaled iso-
flurane to standard intravenous propofol and/or midazo-
lam (Fig. 1). This trial was approval by the ethical
committee of the Toronto General Hospital, University
Health Network (protocol number 13-5845) and Uni-
versity of Ottawa Heart Institute (protocol number
201402500 01H). This clinical trial was originally reg-
istered (NCT01983800) on 2 July 2013.
Eligibility
Patients eligible to be enrolled in this trial are adult ICU
patients (>18 years) within 72 h of critical care admis-
sion and who are expected to require mechanical venti-
lation and sedation for longer than 48 h. The following
criteria exclude patients from participation in this study:
(1) age <18 years; (2) history or family history of ma-
lignant hyperthermia; (3) history of propofol infusion
syndrome; (4) evidence of raised intracranial pres-
sure; (5) 6-month mortality risk from pre-existing
condition >50 %; (6) use of inhaled Flolan (prostacyc-
lin), which is incompatible with the AnaConDa™ de-
vice; (7) low tidal volumes (<350 ml) and one-lung
ventilation; (8) lack of commitment to ongoing crit-
ical care treatment; and (9) pregnancy.
Recruitment
The study coordinator will assess patients daily for study
eligibility within the medical-surgical (MSICU), cardio-
vascular (CVICU) and coronary (CICU) at TGH and
CVICU at Ottawa. Either patient or surrogate decision-
maker consent will be obtained prior to study enroll-
ment. Because most patients will be sedated and not
Population




Inhaled isoflurane sedation +/-
intravenous opioid
Control (20 patients)
Intravenous Midazolam 1-10 mg/h and/or 
propofol < 200/mcg/min +/-
intravenous opioid
Outcomes 
Primary:  Atmospheric volatile levels, protocol adherence and study recruitment
Secondary: Duration mechanical ventilation, extubation time, delirium, quality of sedation, 
vasoactive drug support, length of stay, serum fluoride levels, patient mortality
Exclusion 
1.  Age < 18 years                                           
2.  History malignant hyperthermia                   
3.  History of propofol infusion syndrome   
4.  Evidence of raised intracranial pressure
5.  Use of Flolan (epoprostenol sodium)
6.  Low tidal volumes (< 350 ml) + one-lung 
ventilation
7.  6-month mortality risk from pre-existing 
condition > 50%
8.  Lack of commitment to ongoing treatment 
9.  Pregnancy
Fig. 1 Flow of participants
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have the capacity to provide informed consent, the major-
ity of patients will be consented using surrogate decision-
maker consent from the patient’s legal representative.
Randomization and allocation concealment
This two-arm RCT will randomize 60 patients to the
intervention arm, where patients will receive inhaled
isoflurane volatile-based sedation, or to the control
arm, where the patients will receive standard intraven-
ous midazolam and/or propofol. To further strengthen
assessment of the safety of administering volatile
agents, patients are allocated 2:1 within the interven-
tion:control groups. Patients will be randomized using
a computer sequence generator with permutated
blocks (www.randomization.com). To maximize con-
cealment, the size of the block will not be revealed,
and randomization will only be performed after pa-
tient recruitment. Patients are randomized by the
study coordinator, and allocation concealment is
maintained by using sequentially numbered, opaque,
sealed envelopes.
Study intervention
Sedation within the two arms of this RCT consists of the
following:
Intervention - Inhaled isoflurane (0 to 5 ml/h)
Control - Intravenous midazolam (1 to 10 mg/h) and/
or propofol (<200 mcg/kg/min)
Sedation and pain management in both arms will
be guided using an explicit bedside sedation-analgesia
algorithm (Fig. 2). Sedation in both arms will be ti-
trated every hour to target a Riker Sedation-Agitation
Score (SAS) of 3 to 4 (or as clinically indicated) until
extubation or tracheostomy. Patients will be reviewed
daily for assessment of withdrawing sedation to assist
ventilator weaning (resolving the underlying pathology
that led to mechanical ventilation; patient capable of mak-
ing respiratory effort; PaO2/FiO2 > 150 to 200 mmHg;
PEEP 5 to 8 cm H2O; satisfactory hemodynamic stability
with mean arterial pressure >60 mmHg, which maybe
assisted with stable doses of vasoactive drug support; and
a Assess pain score using 0-10 visual analogue ± numerical pain score or Critical Care Pain 
Observation Tool (CPOT).  If pain score > 3 use fentanyl infusion (25-200 mcg/hour) or
morphine infusion (1-10 mg/hour) or intermittent opioid boluses (fentanyl, hydromorph, 
morphine) 
b Management of acute + severe agitation: Propofol/midazolam group - Consider bolus dose 
of midazolam 0.5-2 mg and/or propofol 10-50 mg; Isoflurane group - administer 0.1-0.5 ml 
bolus.  Caution Hypotension may occur with bolus dosing within either group
Will the patient require mechanical ventilation > 48 hours?




Intravenous propofol and/or midazolam
Propofol  max. 200 mcg/kg/min
Midazolam  max. 10 mg/hour
Hourly assessment of sedation score using SASa 
(aim SAS 3-4 unless clinically specified otherwise)
SAS 3-4






Daily assessment of sedation withdrawal and extubation if:-
A - Patent gag reflex & adequate cough
B - FiO2 < 0.5 & PEEP < 5 cmH2O, respiratory rate/tidal volume 105, SpO2 > 94%
C - Hemodynamically stable
D - Obeys commands, strong hand grip or can head lift > 5 seconds
E - Cuff leak present on endotracheal tube balloon deflation, positive spontaneous  
breathing trial using CPAP 5cmH2O or T-Piece





Opioid ( fentanyl 10mcg/hr 
or morphine 1 mg/hr)
Inhaled isoflurane
Isoflurane 0.5-1 ml/hr
Opioid infusion ( fentanyl 




Opioid infusion ( fentanyl 






Opioid ( fentanyl 10mcg/hr 
or morphine 1 mg/hr)
Fig. 2 Sedation - analgesia algorithm
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no evidence of acute myocardial ischemia) and extubated
according to the criteria outlined in Fig. 2. Pain scores will
be monitored hourly in both groups using the critical care
pain observation tool (CPOT) and numerical pain score
[5]. Pain will be managed in both arms using intravenous
opioids (fentanyl, hydromorphone, or morphine) aiming
for pain scores below 3.
Specialized equipment set-up for volatile sedation
Isoflurane is infused into the AnaConDa™ device,
which is placed between the endotracheal tube and
the ventilator breathing circuit. The device is changed
every 24 h. Isoflurane volatile agent is infused into
the device using the Medfusion 3500™ syringe pump
driver (Smith Medical, St. Paul, Minnesota, US). A
unique and simple syringe driver program for isoflur-
ane has been designed to improve safety of adminis-
tration. This program includes infusion rate limits in
accordance with the sedation protocol, dose range for
rapid bolus administration and a keypad automated
lock system. Scavenging within the ICU will be per-
formed by standard room air exchanges and active vola-
tile scavenging using our previously described and tested
system [21]. This consists of two canisters of Delta-
sorb™ (Blue-Zone, Concord, Ontario, Canada) assem-
bled in a series from the ventilator expiratory port to
the wall outlet suction, which prevents any venting to
the atmosphere. Deltasorb™ contains a lattice matrix
of silica zeolite, which adsorbs volatile agents. Capno-
graphy and end-tidal gas monitoring will be per-
formed at the bedside using the Datex AS/3™ monitor
(DRE Inc, Lousiville, Kentucky, US) or Vamos™ monitor
(Draeger, Ontario, Canada) monitors. When patients are
being prepared for extubation, study sedation drugs will
be discontinued, and the AnaConDa™ device will be re-
moved from the breathing circuit, given its high recycling
properties, to facilitate a quick drug washout.
Staff education and training
This trial involves the use of a new mediation and delivery
system for ICUs staffed by non-anesthesiologists. Thus,
education of medical, nursing and respiratory therapy staff
regarding sedation practice and the use of volatile agents
is supported by the development of a formal written and
lecture-based teaching program. A practical bedside hand-
book and in-depth teaching manual was specifically de-
signed for this study for critical care teams with limited or
no anesthesia experience.1 Training sessions include infor-
mation regarding the roles of the multidisciplinary team,
use of the AnaConDa™ device, equipment set-up, trouble-
shooting, nebulization of drugs, transport of the critical
care patient and safety monitoring. Participants finishing
the training session will be completing a confidential
questionnaire using a 1 to 5 Likert scale, which will assess
the quality of the education. A pre- and post-study ques-
tionnaire will be performed to assess staff experience,
knowledge, and opinions on using inhalational and intra-
venous sedation before and after this pilot trial. Nursing
and respiratory therapy staff actively involved in the care
of enrolled patients will be asked to record their daily sat-
isfaction score regarding both sedation modalities.
Blinding
Blinding of this study to the healthcare team, patient
family and data collectors is not possible given the sig-
nificant differences in the equipment and bedside moni-
toring. The data will be blinded to the data analyst.
Equipment licensing and approvals
The AnaConDa™ device is licensed for use in Canada
and Health Canada approval has been granted for the




This pilot trial will primarily assess the sedation-analgesia
protocol feasibility and safety by measuring atmospheric
volatile concentration levels; see the Project evaluation
and data collection for details.
Secondary outcomes
The following secondary clinical endpoints will be
recorded:
1. Time to extubation (time between discontinuing
sedation and tracheal extubation)
2. Duration of mechanical ventilation
3. Quality of sedation assessed by
a) Number hours per day target SAS achieved daily
b) Number of sedation boluses administered per day
c) Opioid requirement
d) Additional sedative and anti-psychotic drugs, for
example, morphine BDZ, haloperidol
4. Incidence of delirium
5. Vasopressor/inotropic support
6. Serum fluoride levels (μmol/L)
7. ICU and hospital length of stay
8. ICU and hospital mortality
Project evaluation and data collection
For patients within the volatile group, daily atmos-
pheric volatile levels (parts per million) will be mea-
sured using photometric multigas infrared analyzer
(InfraRan™ Specific Vapor Analyzer, Wilkins Enterprise
Inc., Massachusetts, USA) to ensure staff safety during
volatile use. The InfraRan™ is a bedside gas analyzer,
which allows the operator to determine which gas is
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being measured and calibrated prior to use. Measure-
ment will be performed at four points along the breath-
ing circuit: (1) expiratory limb of the ventilator, (2) post
1st Deltasorb, (3) post 2nd Deltasorb and (4) room
levels around the patient’s head [21]. These measure-
ments will be performed by the study coordinator who
is trained to use the InfraRan analyzer™. Room levels
above 2 ppm indicate high levels of atmospheric pollu-
tion, which require immediate equipment assessment
for leaks and inadequate room scavenging.
Adherence and violations of the sedation protocol will
be assessed by inappropriate equipment set-up and fail-
ure to titrate sedation to the target SAS score. This will
be assessed by daily equipment checks by a member of
the study team. The bedside nurse will record hourly ac-
tual and target SAS scores. Protocol violations include
no attempt in change in sedative-analgesic regime by the
bedside nurse when the actual sedation score fails to
meet the target sedation score for more than 2 h. In
addition, we will seek feedback and document satisfac-
tion scores from the bedside nurse and respiratory ther-
apist regarding the protocol using a 1 to 5 Likert scale.
A screening log of eligible non-randomized patients will
also be kept. This will be reviewed to explore reasons for
non-enrollment, for example, the study exclusion criteria
or refusal by patient’s legal representative or attending
physician.
Serum fluoride levels will be measured at 24 h after
commencing sedation, followed by further samples every
48 h during sedation with two additional levels mea-
sured after discontinuing sedation to assess fluoride
washout. Serum fluoride levels will be measured in both
treatment groups in order to understand the difference
in fluoride levels from volatile sedation; many patients
within our two sites have undergone recent surgery
where anesthesia is often maintained using volatile
agents. The study coordinator will collect 3 to 5 ml of
blood in an EDTA tube, which is centrifuged at 2000 g
at −30 °C. The plasma is collected and immediately fro-
zen at −70 °C and subsequently fluoride levels are ana-
lyzed at a specialized laboratory. Serum fluoride levels
will be correlated with the patient’s renal function as
assessed using serum creatinine and glomerular filtration
rate to look for any associated nephrotoxicity.
Patient demographics, APACHE (Acute Physiology
and Chronic Health Evaluation) score, hemodynamic
variables and vasoactive drug support, ventilation me-
chanics, laboratory investigations, clinical ICU compli-
cations, length of stay, and mortality will be recorded
by daily patient assessment and review of paper and
electronic health records. Delirium will be assessed
twice daily using the Confusion Assessment Method
(CAM-ICU) or Intensive Care Delirium Screening
Checklist (ICDSC) [5].
Sample size and time line
This pilot study will recruit 60 patients over 2 years. Be-
cause this pilot trial is designed to mainly assess the
feasibility of our protocol and the safety of running vola-
tile agents for ICU sedation, we believe 60 patients will
be adequate and in keeping with other pilot studies [25].
This will adequately assess the initial feasibility and
safety of using volatile agents for long-term sedation. A
total of 66 patients will be recruited to accommodate a
10 % attrition rate. We calculated the sample size for a
larger trial based on logarithmic transformation of our
preliminary analysis of our short-term sedation results,
which demonstrated median extubation times of 178
and 285 min within the volatile and propofol groups,
respectively [19]. To demonstrate a moderate Cohen’s
effect size with a two-sided α of 0.05 and 90 %
power, 170 patients will be required. With an attrition
rate of 10 %, the final sample size for randomization
is 188 (94 patients per arm).
Statistical analysis
Continuous parametric variables such as atmospheric
volatile levels, serum fluoride levels will be recorded
as mean (standard deviation) and analyzed using a
two-sample independent t-test. All nonparametric
data such as satisfaction scores will be recorded as
median (interquartile range) and analyzed using the
Mann Whitney U test. Binary data such as gender,
comorbidities will be recorded as proportions and an-
alyzed using the chi-squared or Fishers exact test (if
samples <5). Data will be analyzed by an independent
statistician using SAS version 9.4 software (Cary, NC,
USA). Data analysis will be based on the intention-to-
treat principle.
Discussion
Volatile anesthetics have many pharmacological proper-
ties, making it the ideal sedative agent for prolonged
duration of use in the ICU. Data from this trial will help
us understand the feasibility, acceptance and technical
issues associated with conducting volatile sedation in
ICUs with little or no experience of this technique.
Furthermore, this study will answer important questions
regarding fluoride levels during prolonged volatile-
based sedation and assess the efficacy of our scavenging
system.
Trial status
This trial is actively enrolling patients. Currently, we
have recruited 50 % patients and aim to complete this
pilot trial by June 2016.
Endnotes
1VALTS Study Manual. K Wong, A Jerath July 2013
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